Drawing for WENROVI

USPTO serial 88024355

WENROVI

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
KHOURI, SANI PHILIPPE
Law office
TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with WENROVI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Merilee J. Arevalo

MERILEE J. AREVALO GSK5 MOORE DRIVELBP, 5.5ARESEARCH TRIANGLE PARK, NC 27709-3398

Goods and services

ClassDescriptionStatusFirst use
005(Based on Intent to Use) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; VaccinesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Dec 24, 2019MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Dec 23, 2019ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 11, 2019GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jun 11, 2019GNSIINQUIRY TO SUSPENSION E-MAILED—
Jun 11, 2019CNSISUSPENSION INQUIRY WRITTEN—
Nov 21, 2018GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 21, 2018GNSLLETTER OF SUSPENSION E-MAILED—
Nov 21, 2018CNSLSUSPENSION LETTER WRITTEN—
Sep 27, 2018FIXDELECTRONIC RECORD REVIEW COMPLETE—
Sep 27, 2018ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Sep 21, 2018ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 19, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 12, 2018DOCKASSIGNED TO EXAMINER—
Jul 9, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 6, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance